Q3 2024 Earnings Estimate for Sarepta Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at Leerink Partnrs raised their Q3 2024 earnings per share estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Wednesday, May 1st. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings per share of $1.39 for the quarter, up from their previous forecast of $1.37. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $4.20 EPS, FY2024 earnings at $5.88 EPS and FY2025 earnings at $11.58 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.32% and a net margin of 1.20%. The company’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.44) earnings per share.

A number of other analysts also recently issued reports on SRPT. JPMorgan Chase & Co. lowered their target price on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating on the stock in a research report on Friday. Evercore ISI lifted their target price on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. BMO Capital Markets began coverage on Sarepta Therapeutics in a research report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $224.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Finally, UBS Group boosted their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $160.60.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $133.66 on Friday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. The stock’s 50-day simple moving average is $125.69 and its 200 day simple moving average is $110.70. The company has a market cap of $12.63 billion, a P/E ratio of -21.84 and a beta of 0.95. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $159.89.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principal Securities Inc. bought a new stake in Sarepta Therapeutics during the fourth quarter worth $26,000. Mather Group LLC. acquired a new position in shares of Sarepta Therapeutics during the first quarter worth $28,000. Montag A & Associates Inc. acquired a new position in shares of Sarepta Therapeutics during the third quarter worth $30,000. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Insider Activity at Sarepta Therapeutics

In related news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares in the company, valued at $3,457,550.24. The sale was disclosed in a filing with the SEC, which is available at this link. In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at $2,815,030. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now owns 26,836 shares of the company’s stock, valued at $3,457,550.24. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,096 shares of company stock worth $2,739,419. Company insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.